The most recent molecular target suggested for CTX is Neuropilin-1 (NRP-1), a vascular endothelial growth factor (VEGF) [54,55,164] known to be overexpressed in many cancers but naturally upregulated in normal lung and heart tissues [165,166,167,168]. Here, NRP1 is linked to cancer.